Navigation Links
Hovione: EPO Grants a New Inhaler Patent
Date:9/11/2013

ur business partners to take advantage of additional patent protection for their inhalation drug product and effective drug product life cycle management" said Gonçalo Andrade, Business Development Manager.

Hovione is currently executing inhaled drug development projects for multiple pharmaceutical companies, involving API process development, particle engineering, formulation and clinical supplies and is looking for partners willing to incorporate the XCaps into their inhalation drug development.

About Hovione. Hovione is a global company with over 50 years' experience in Active Pharmaceutical Ingredient and Drug Product Intermediate development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers in the most regulated markets. Hovione offers integrated API, particle design, formulation development and GMP manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

More about XCaps at http://www.hovione.com/inhale

Contacts at Hovione:
Gonçalo Andrade, PhD                Isabel Pina
Business Development Manager        Director Corporate Communications
gandrade@hovione.com                ipina@hovione.com
+351-219-847-619                    +351-21-982-9362

http://www.hovione.com


'/>"/>
SOURCE Hovione
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
2. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
3. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
4. NSF CAREER grants support ocean energy, microforming, computer planning
5. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
6. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
7. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
8. USPTO Grants Butamax a Further KARI Enzyme Patent
9. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... reported financial results for the second quarter 2015. ... we remain on track to achieve our commercial and ... Officer of the Company. "Since our last quarterly earnings ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Inc. (NYSE Amex: PTN ) today announced the ... of 23,000,000 shares of its common stock, Series A Warrants ... B Warrants to purchase 21,000,000 shares of its common stock, ... Palatin expects that the net proceeds of the offering will ...
... ViroPharma Incorporated (Nasdaq: VPHM ) reported today ... December 31, 2010. In 2010, we: ... including $177 million in net sales of Cinryze® (C1 esterase ... million, representing 88 percent growth over the prior year; GAAP ...
... Incorporated (NYSE: DGX ), the world,s leading ... that it has signed a definitive agreement to acquire ... for neurological disorders, from Thermo Fisher Scientific (NYSE: ... Athena Diagnostics is the leading provider of ...
Cached Biology Technology:Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 11Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 2Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 3Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 4
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... 22, 2012) Researchers at Columbia University Medical Center ... retention and release of the brain,s stem cells. The ... development and could eventually lead to regenerative therapies for ... effort of the laboratories of Drs. Anna Lasorella and ...
... Public health was not part of the initial ... is little information about any health impacts of the technologies ... of Medicine will use hydraulic fracturing, or "fracking," as a ... to identify and explore potential health consequences of emerging energy ...
... The March of Dimes Foundation has chosen University ... Kuyumcu-Martinez to receive a two-year, $150,000 Basil O,Connor Starter ... congenital heart defects, the most common type of major ... receive this prestigious award," Kuyumcu-Martinez said. "I,m very thankful ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3UTMB scientist awarded $150,000 by March of Dimes 2
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
... Phosphate Assay Kit is based on quantification ... Green, molybdate and free orthophosphate. The rapid ... conveniently measured on a spectrophotometer (600-660 nm) ... colorimetric assay kits have been optimized to ...
... is a lyophilized mixture of five ... weights range from 152 to 504. ... with the Aminex HPX-87C column and ... testing or semiquantitative determination. Supplied as ...
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Biology Products: